1-12 of 12
Yael P. Mossé
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A009: Proteogenomic prioritization of immunotherapeutic targets in rhabdomyosarcoma nominate MEGF10 for preclinical development

Rawan Shraim, Amber K. Weiner, Karina L. Conkrite, Alexander B. Radaoui, John M. Maris, Yael P. Mosse, Sharon J. Diskin, Ahmet Sacan, Benjamin A. Garcia, Peter J. Houghton, Raushan T. Kurmasheva, Poul Sorensen, Gregg B. Morin, Brian Mooney
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18_Supplement): A009.
https://doi.org/10.1158/1557-3265.SARCOMAS22-A009
Published: 15 September 2022
View article titled, Abstract A009: Proteogenomic prioritization of immunotherapeutic targets in rhabdomyosarcoma nominate MEGF10 for preclinical development
Journal Articles

Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)

Jennifer H. Foster, Stephan D. Voss, David C. Hall, Charles G. Minard, Frank M. Balis, Keith Wilner, Stacey L. Berg, Elizabeth Fox, Peter C. Adamson, Susan M. Blaney, Brenda J. Weigel, Yael P. Mossé
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (13): 3543–3548.
https://doi.org/10.1158/1078-0432.CCR-20-4224
Published: 01 July 2021
View article titled, Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)
Open the PDF for Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912) in another window
Includes: Supplementary data
Journal Articles

The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models

Nathan M. Kendsersky, Jarrett Lindsay, E. Anders Kolb, Malcolm A. Smith, Beverly A. Teicher, Stephen W. Erickson, Eric J. Earley, Yael P. Mosse, Daniel Martinez, Jennifer Pogoriler, Kateryna Krytska, Khushbu Patel, David Groff, Matthew Tsang, Samson Ghilu, Yifei Wang, Steven Seaman, Yang Feng, Brad St. Croix, Richard Gorlick, Raushan Kurmasheva, Peter J. Houghton, John M. Maris
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (10): 2938–2946.
https://doi.org/10.1158/1078-0432.CCR-20-4221
Published: 15 May 2021
View article titled, The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models
Open the PDF for The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models in another window
Includes: Supplementary data
Journal Articles

A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)

Yael P. Mossé, Elizabeth Fox, David T. Teachey, Joel M. Reid, Stephanie L. Safgren, Hernan Carol, Richard B. Lock, Peter J. Houghton, Malcolm A. Smith, David Hall, Donald A. Barkauskas, Mark Krailo, Stephan D. Voss, Stacey L. Berg, Susan M. Blaney, Brenda J. Weigel
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (11): 3229–3238.
https://doi.org/10.1158/1078-0432.CCR-18-2675
Published: 03 June 2019
View article titled, A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)
Open the PDF for A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921) in another window
Includes: Supplementary data
Journal Articles

Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

Steven G. DuBois, Yael P. Mosse, Elizabeth Fox, Rachel A. Kudgus, Joel M. Reid, Renee McGovern, Susan Groshen, Rochelle Bagatell, John M. Maris, Clare J. Twist, Kelly Goldsmith, M. Meaghan Granger, Brian Weiss, Julie R. Park, Margaret E. Macy, Susan L. Cohn, Greg Yanik, Lars M. Wagner, Randall Hawkins, Jesse Courtier, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Najee Boucher, Scarlett Czarnecki, Chunqiao Luo, Denice Tsao-Wei, Katherine K. Matthay, Araz Marachelian
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (24): 6142–6149.
https://doi.org/10.1158/1078-0432.CCR-18-1381
Published: 13 December 2018
View article titled, Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
Open the PDF for Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma in another window
Includes: Supplementary data
Journal Articles

Retinoblastoma and Neuroblastoma Predisposition and Surveillance

Junne Kamihara, Franck Bourdeaut, William D. Foulkes, Jan J. Molenaar, Yaël P. Mossé, Akira Nakagawara, Andreu Parareda, Sarah R. Scollon, Kami Wolfe Schneider, Alison H. Skalet, Lisa J. States, Michael F. Walsh, Lisa R. Diller, Garrett M. Brodeur
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (13): e98–e106.
https://doi.org/10.1158/1078-0432.CCR-17-0652
Published: 02 July 2017
View article titled, Retinoblastoma and Neuroblastoma Predisposition and Surveillance
Open the PDF for Retinoblastoma and Neuroblastoma Predisposition and Surveillance in another window
Journal Articles

Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma

Andrew C. Wood, Kateryna Krytska, Hannah T. Ryles, Nicole R. Infarinato, Renata Sano, Theodore D. Hansel, Lori S. Hart, Frederick J. King, Timothy R. Smith, Edward Ainscow, Kathryn B. Grandinetti, Tove Tuntland, Sunkyu Kim, Giordano Caponigro, You Qun He, Shiva Krupa, Nanxin Li, Jennifer L. Harris, Yaël P. Mossé
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11): 2856–2868.
https://doi.org/10.1158/1078-0432.CCR-16-1114
Published: 31 May 2017
View article titled, Dual <em>ALK</em> and <em>CDK4/6</em> Inhibition Demonstrates Synergy against Neuroblastoma
Open the PDF for Dual <em>ALK</em> and <em>CDK4/6</em> Inhibition Demonstrates Synergy against Neuroblastoma in another window
Includes: Supplementary data
Journal Articles

Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma

Kateryna Krytska, Hannah T. Ryles, Renata Sano, Pichai Raman, Nicole R. Infarinato, Theodore D. Hansel, Monish R. Makena, Michael M. Song, C. Patrick Reynolds, Yael P. Mossé
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (4): 948–960.
https://doi.org/10.1158/1078-0432.CCR-15-0379
Published: 14 February 2016
View article titled, Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma
Open the PDF for Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma in another window
Includes: Supplementary data
Journal Articles

Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies

Yael P. Mossé
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (3): 546–552.
https://doi.org/10.1158/1078-0432.CCR-14-1100
Published: 31 January 2016
View article titled, Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies
Open the PDF for Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies in another window
Journal Articles

Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study

Yael P. Mossé, Emily Lipsitz, Elizabeth Fox, David T. Teachey, John M. Maris, Brenda Weigel, Peter C. Adamson, Mark A. Ingle, Charlotte H. Ahern, Susan M. Blaney
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (21): 6058–6064.
https://doi.org/10.1158/1078-0432.CCR-11-3251
Published: 06 November 2012
View article titled, Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study
Open the PDF for Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study in another window
Journal Articles

Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial

Steven G. DuBois, Louis Chesler, Susan Groshen, Randall Hawkins, Fariba Goodarzian, Hiroyuki Shimada, Greg Yanik, Michael Tagen, Clinton Stewart, Yael P. Mosse, John M. Maris, Denice Tsao-Wei, Araz Marachelian, Judith G. Villablanca, Katherine K. Matthay
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (9): 2679–2686.
https://doi.org/10.1158/1078-0432.CCR-11-3201
Published: 30 April 2012
View article titled, Phase I Study of Vincristine, Irinotecan, and <sup>131</sup>I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
Open the PDF for Phase I Study of Vincristine, Irinotecan, and <sup>131</sup>I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial in another window
Includes: Supplementary data
Journal Articles

Inhibition of ALK Signaling for Cancer Therapy

Yael P. Mossé, Andrew Wood, John M. Maris
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (18): 5609–5614.
https://doi.org/10.1158/1078-0432.CCR-08-2762
Published: 14 September 2009
View article titled, Inhibition of ALK Signaling for Cancer Therapy
Open the PDF for Inhibition of ALK Signaling for Cancer Therapy in another window